Unsafe
Unsafe
Patient Risk:
High
Summary
The claims largely align with the label on mechanism, indications (cardiovascular risk reduction and glycemic control), and administration. However, there are significant safety omissions (boxed warnings, contraindications, pregnancy/pediatric use, pancreatitis/gallbladder risk, hypoglycemia with insulin/sulfonylureas, renal/hepatic considerations, and retinopathy monitoring) that substantially diminish safety alignment.
Category Scores
Accurate Statements
Ozempic is semaglutide, a GLP-1 receptor agonist.
12.1
Ozempic is administered via subcutaneous injection.
2.1
Ozempic reduces the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease.
1
Ozempic improves glycemic control in adults with type 2 diabetes.
14.1
GLP-1 stimulates insulin secretion and suppresses glucagon production.
12.2
Semaglutide lowers fasting and postprandial glucose concentrations, contributing to improved glycemic control.
12.2
Unsupported Statements
Ozempic was first approved by the FDA in 2017 for the treatment of type 2 diabetes.
Label sections provided do not include a historical approval date.
Ozempic has gained popularity for its potential to promote weight loss and improve glycemic control.
Label discusses glycemic control and weight effects but does not address popularity.
Ozempic reduces sugar cravings and improves glucose metabolism in patients with type 2 diabetes.
Label supports glycemic control and glucose metabolism changes but does not claim reductions in sugar cravings.
GLP-1 receptor agonists like Ozempic can reduce food cravings and improve eating behavior.
Not stated in the provided labeling sections.
GLP-1 plays a crucial role in regulating sugar intake.
Not stated in the provided labeling sections.
When we eat, GLP-1 is released in response to glucose and helps to regulate blood sugar levels.
Not stated in the provided labeling sections.
Ozempic has also been shown to promote significant weight loss in patients with type 2 diabetes.
Not explicitly reported in the provided labeling sections.
Ozempic produced a mean weight loss of 5.3 kg (11.7 lbs) over 26 weeks.
Not explicitly reported in the provided labeling sections.
Like all medications, Ozempic can cause side effects.
Label discusses adverse reactions but the generic phrasing is not directly quoted from the label.
The benefits of Ozempic often outweigh the risks, and it is generally considered safe when used as directed.
No such overall risk-benefit framing is provided in the supplied label sections.
Contradictions
Important Omissions
Boxed Warning: risk of thyroid C-cell tumors; contraindications related to MTC and MEN 2.
Importance:
High
Contraindications explicitly including personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
Importance:
High
Initiation dosing and titration details (starting at 0.25 mg weekly for 4 weeks, then escalation to 0.5 mg, 1 mg, and up to 2 mg weekly).
Importance:
High
Pregnancy and contraception guidance; pediatric use information.
Importance:
High
Pancreatitis and cholelithiasis warnings; hypoglycemia risk with concomitant insulin or sulfonylureas; renal and hepatic impairment considerations.
Importance:
High
Retinopathy considerations with rapid glycemic control and ophthalmologic monitoring guidance if applicable.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Critical safety gaps in the claims, including absence of boxed warnings and contraindications, lack of dosing titration details, and omission of key adverse event and monitoring considerations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Unsafe
Primary Issue
Significant safety omissions and incongruent dosing information; multiple labeled safety risks not addressed.
Suggested Improvement
Incorporate Boxed Warning language and contraindications (MTC/MEN 2); add explicit initiation and titration dosing (0.25 mg x 4 weeks, then 0.5 mg, 1 mg, up to 2 mg weekly); include pregnancy/ contraception guidance and pediatric use; add pancreatitis, cholelithiasis, hypoglycemia risk with concomitant antidiabetic agents, renal/hepatic considerations, and retinopathy monitoring guidance; ensure all claims map to exact label sections (2.x, 4.x, 5.x, 8.x, 12.x, 14.x).